| Literature DB >> 28140525 |
Ronan Crépin1, David Gentien2, Angeline Duché2, Audrey Rapinat2, Cecile Reyes2, Fariba Némati2, Gérald Massonnet2, Didier Decaudin2,3, Selma Djender1,4, Sandrine Moutel2,4,5, Klervi Desrumeaux1, Nathalie Cassoux6, Sophie Piperno-Neumann7, Sebastian Amigorena4,8,9,10, Franck Perez1,4,5, Sergio Roman-Roman2, Ario de Marco1,9,10,11.
Abstract
Monoclonal antibodies specific for biomarkers expressed on the surface of uveal melanoma (UM) cells would simplify the immune capture and genomic characterization of heterogeneous tumor cells originated from patient-derived xenografts (PDXs). Antibodies against four independent tumor antigens were isolated by panning a nanobody synthetic library. Such antibodies enabled flow cytometry-based sorting of distinct cell subpopulations from UM PDXs and to analyze their genomic features. The complexity and specificity of the biochemical and genomic biomarker combinations mirrored the UM tumor polyclonality. The data showed that MUC18 is highly and universally displayed on the surface of UM cells with different genetic background and consequently represents a reliable pan-biomarker for their identification and purification. In contrast, the other three biomarkers were detected in very variable combinations in UM PDX cells. The availability of the identified nanobodies will be instrumental in developing clone-specific drug evaluation and rational clinical strategies based on accurate genomic profiling.Entities:
Keywords: MUC18; membrane surface biomarkers; nanobodies; panning; patient-derived xenografts; tumor polyclonality; uveal melanoma
Mesh：
Substances：
Year: 2017 PMID： 28140525 DOI： 10.1111/pcmr.12577
Source DB: PubMed Journal: Pigment Cell Melanoma Res ISSN： 1755-1471 Impact factor: 4.693